Idiopathic epiretinal membrane, macular hole Idiopathic epiretinal membrane, macular hole
Conditions
Interventions
One drop of Brimonidine/Timolol fixed combination ophthalmic solution is instilled twice-daily for 8 days (7
days before surgery and the operation day in the morning and at 2h before surgery).
Sponsors
Inatani Masaru
Senju Pharmaceutical Co.,Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with written informed consent obtained after adequate explanation on participating the study 2)Male or female, 20 years of age or older 3)Patients who undergo vitrectomy for idiopathic epiretinal membrane or macular hole
Exclusion criteria
Exclusion criteria: 1)Patients with ocular inflammation 2)Patients with vitreous hemorrhage 3)Patients with proliferative diabetic retinopathy 4)Patients with severe corneal epithelium disorder 5)Patients with contraindications or patients in whom precautions are required for the use of Brimonidine/Timolol fixed combination. 6)Patients with a history of serious side effects against alpha 2-adrenergic receptor agonist or beta-adrenergic receptor inhibitor 7)Patients who have been considered inappropriate as study subjects by doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of brimonidine in the aqueous humor and vitreous | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentration of timolol in the aqueous humor and vitreous, Correlation between concentration of drugs in the aqueous humor and vitreous and patient background, adverse events, visual acuity, intraocular pressure, blood pressure, pulse, ophthalmologic findings (cornea, conjunctiva) | — |
Contacts
Public ContactMasaru Inatani
University of Fukui Hospital
Outcome results
None listed